Effective. Feb. 4, 2026, Dalvance® will be removed from medical drug coverage for commercial group and individual members and replaced with its generic, Dalbavancin. Dalbavancin has been added to medical drug coverage with prior authorization and site of service requirements for these members.
What does it treat?
Dalvance is a one or two-dose injection drug used to treat acute bacterial skin and skin structure infections.